Fed. Circ. Clears Actavis In Generic Lialda Patent Suit
The Federal Circuit ruled Friday that Actavis Inc.'s planned generic version of the bowel disease drug Lialda does not infringe Shire Development LLC's patent, reversing a lower court's decision....To view the full article, register now.
Already a subscriber? Click here to view full article